Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

The meeting is a popular venue for dealmaking and discussions between pharma and biotech companies. Investors are eager to see more of Moderna’s pipeline become approved products. Moderna had ...

Moderna may reach its product approval and launch goals -- but this will take a few years. Meanwhile, the market could continue to sanction the biotech if sales remain lackluster in 2025.